Patents by Inventor Ronald Breslow

Ronald Breslow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040002506
    Abstract: The present invention provides the compound having the formula: 1
    Type: Application
    Filed: October 25, 2002
    Publication date: January 1, 2004
    Applicants: Sloan Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York
    Inventors: Ronald Breslow, Sandro Belvedere, Leland Gershell, Thomas A. Miller, Paul A. Marks, Victoria M. Richon, Richard A. Rifkind
  • Publication number: 20030134824
    Abstract: The invention provides &bgr;-cyclodextrin dimers and phthalocyanines which can be used in photodynamic therapy of cancer.
    Type: Application
    Filed: November 12, 2001
    Publication date: July 17, 2003
    Inventors: Ronald Breslow, Simon D.P. Baugh
  • Patent number: 6511990
    Abstract: The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: January 28, 2003
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York
    Inventors: Ronald Breslow, Sandro Belvedere, Leland Gershell, Thomas A. Miller, Paul A. Marks, Victoria M. Richon, Richard A. Rifkind
  • Publication number: 20030013176
    Abstract: The present invention provides three-dimensional structural information from the hyperthermophilic bacterium Aquifex aeolicus which is a histone deacetylase-like protein (HDLP). HDLP shares 35.2% amino acid sequence identity with human histone deacetylase (HDAC1). The present invention further provides three-dimensional structural information of HDLP bound by inhibitor molecules. The three-dimensional structural information of the present invention is useful to design, isolate and screen deacetylase inhibitor compounds capable of inhibiting HDLP, HDAC family members and HDLP-related molecules. The invention also relates to nucleic acids encoding a mutant HDLP which facilitates the determination of the three-dimensional structure of HDLP in the presence of a zinc atom.
    Type: Application
    Filed: March 8, 2002
    Publication date: January 16, 2003
    Inventors: Nikola Pavletich, Michael Finnin, Jill Donigian, Victoria M. Richon, Richard A. Rifkind, Paul A. Marks, Ronald Breslow
  • Patent number: 6331530
    Abstract: The invention provides a composition of matter comprising two &bgr;-cyclodextrin molecules and a cleavable linker attached to and joining each such &bgr;-cyclodextrin. This invention further provides a composition which comprises a hydrophilic matrix comprising the above-described composition of matter and a photosensitizer encapsulated within the matrix, wherein the cleavable linker is cleaved upon exposure to light of a wavelength appropriate for the light to be absorbed by the photosensltlzer. This invention also provides a method of killing a tumor cell which comprises bringing into proximity with the tumor cell the above-described composition and exposing the composition to light so as to cleave the cleavable linker and release the photosensitizer.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: December 18, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Ronald Breslow, Anja Ruebner, Zhiwei Yang
  • Patent number: 6103892
    Abstract: The present invention provides a metalloporphyrin catalyst represented by the structure: ##STR1##
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: August 15, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Ronald Breslow, Jerry Yang, Bartolo Gabriele
  • Patent number: 6093812
    Abstract: This invention provides an improved process for producing azetidinones. More particularly, this invention provides the steps of producing an trans-azetidinone represented by the formula ##STR1## from a carboxylic acid R.sup.2 --D--CH.sub.2 COOH, an aldehyde R.sup.1 --A--CHO and an amine RNH.sub.2, by the steps of: (a1) converting a carboxylic acid to the corresponding acid chloride; (b1) deprotonating a chiral oxazolidinone and treating the resulting anion with the product of step (a1); (c1) enolizing the product of step (b1) and condensing with the aldehyde; (d1) hydrolyzing the product of step (c1); (e1) condensing the product of step (d1) with the amine; and (f1) cyclizing the product of step (e1). Alternatively, the process comprises (a2) enolizing the product of step (b1) and condensing, in the presence of a Lewis acid, with a Schiff's base prepared from the aldehyde and the amine; and (b2) cyclizing the product of step (a2).
    Type: Grant
    Filed: January 7, 1994
    Date of Patent: July 25, 2000
    Assignee: Schering Corporation
    Inventors: Tiruvettipuram K. Thiruvengadam, Chou-Hong Tann, Junning Lee, Timothy McAllister, Cesar Colon, Derek H. R. Barton, Ronald Breslow, Anantha Sudhakar
  • Patent number: 6087367
    Abstract: The present invention provides the compound having the structure: ##STR1## wherein each of R.sub.1 and R.sub.2 are independently the same as or different from each other; when R.sub.1 and R.sub.2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R.sub.1 and R.sub.2 are different, R.sub.1 =R.sub.3 --N--R.sub.4, wherein each of R.sub.3 and R.sub.4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R.sub.3 and R.sub.4 bond together to form a piperidine group and R.sub.2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: July 11, 2000
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York
    Inventors: Ronald Breslow, Paul A. Marks, Richard A. Rifkind, Branko Jursic
  • Patent number: 5932616
    Abstract: The present invention provides the compound having the structure: ##STR1## wherein each of R.sub.1 and R.sub.2 are independently the same as or different from each other; when R.sub.1 and R.sub.2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R.sub.1 and R.sub.2 are different, R.sub.1 =R.sub.3 --N--R.sub.4, wherein each of R.sub.3 and R.sub.4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R.sub.3 and R.sub.4 bond together to form a piperidine group and R.sub.2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
    Type: Grant
    Filed: April 4, 1994
    Date of Patent: August 3, 1999
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia Univerisity in the City of New York
    Inventors: Ronald Breslow, Paul A. Marks, Richard A. Rifkind, Branko Jursic
  • Patent number: 5840960
    Abstract: The invention provides compounds, several of which belong to a class having two or more nonpolar components connected by a polar group and having polar groups on the termini of the compound. The invention also concents a method of selectively inducing termini differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effective to selectively induce terminal differentiation. Moreover, the invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells, thereby inhibiting their proliferation and suppressing oncogenicity.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York
    Inventors: Paul A. Marks, Richard A. Rifkind, Ronald Breslow, Branko Jursic
  • Patent number: 5773474
    Abstract: The invention provides a class of compounds and compositions thereof having the structure: ##STR1## wherein A is: ##STR2## The invention also concerns a method of selectively inducing terminal differentiation of neoplastic cells thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an amount of the compound to selectively induce terminal differentiation. It also provides a method of treating a patient having a tumor characterized by proliferatoin of neoplastic cells comprising administration of an amount of the compound effective to inhibit proliferation and suppress oncogenicity of neoplastic cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 30, 1998
    Assignee: The Trustees of Columbia University in the City of New York and Sloan-Kettering Institute for Cancer Research
    Inventors: Ronald Breslow, Paul A. Marks, Richard A. Rifkind
  • Patent number: 5700811
    Abstract: This invention is directed to compounds having the structure: ##STR1## wherein R.sub.1 and R.sub.2 are independently the same as or different from each other; when R.sub.1 and R.sub.2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine or thiazoleamino group; when R.sub.1 and R.sub.2 are different, R.sub.1 =R.sub.3 --N--R.sub.4, and n is an integer from about 4 to about 8. This invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells. The invention further provides pharmaceutical compositions comprising a therapeutically effective amount of the compounds of the present invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 19, 1994
    Date of Patent: December 23, 1997
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ronald Breslow, Paul A. Marks, Richard A. Rifkind
  • Patent number: 5668179
    Abstract: The invention also concerns a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effect to selectively induce terminal differentiation.Moreover, the invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells, thereby inhibiting their proliferation and suppressing oncogenicity.Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound in an amount effective less than an amount which would cause toxicity in the patient.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 16, 1997
    Assignees: The Trustees of Columbia University in the City of New York, Sloan-Kettering Institute for Cancer Research
    Inventors: Ronald Breslow, Paul A. Marks, Richard A. Rifkind
  • Patent number: 5608108
    Abstract: The invention provides compounds, several of which belong to a class having two or more nonpolar components connected by a polar group and having polar groups on the termini of the compound.The invention also concents a method of selectively inducing termini differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effect to selectively induce terminal differentiation.Moreover, the invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells, thereby inhibiting their proliferation and suppressing oncogenicity.
    Type: Grant
    Filed: April 17, 1995
    Date of Patent: March 4, 1997
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia Univeristy in the City of New York
    Inventors: Paul A. Marks, Richard A. Rifkind, Ronald Breslow, Branko Jursic
  • Patent number: 5369108
    Abstract: The present invention provides the compound having the structure: ##STR1## wherein each of R.sub.1 and R.sub.2 are independently the same as or different from each other; when R.sub.1 and R.sub.2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R.sub.1 and R.sub.2 are different, R.sub.1 =R.sub.3 --N--R.sub.4, wherein each of R.sub.3 and R.sub.4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R.sub.3 and R.sub.4 bond together to form a piperidine group and R.sub.2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
    Type: Grant
    Filed: October 4, 1991
    Date of Patent: November 29, 1994
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia
    Inventors: Ronald Breslow, Paul A. Marks, Richard A. Rifkind, Branko Jursic
  • Patent number: 5330744
    Abstract: The present invention provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises treating the cells so as to render them resistant to an antitumor agent and contacting the resulting resistant cells under suitable conditions with an amount of a compound effective to selectively induce terminal differentiation of such cells. The compound has a structure:[R-A ]-B-[A.sub.1 -B.sub.1 -].sub.a [A.sub.2 -B.sub.2 -].sub.b [A.sub.3 -R.sub.1 ].The invention also concerns a method of treating a patient having a tumor characterized by proliferation of neoplastic which comprises administering to the patient an amount of an antitumor agent to render the cells resistant to the antitumor agent and subsequently administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
    Type: Grant
    Filed: November 14, 1988
    Date of Patent: July 19, 1994
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York
    Inventors: Sandro Pontremoli, Ronald Breslow, Paul A. Marks, Richard A. Rifkind
  • Patent number: 5175191
    Abstract: The invention provides compounds, several of which belong to a class having two or more nonpolar components connected by a polar group and having polar groups on the termini of the compound.The invention also concerns a method of selectively inducing termini differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effect to selectively induce terminal differentiation.Moreover, the invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells, thereby inhibiting their proliferation and suppressing oncogenicity.
    Type: Grant
    Filed: May 14, 1990
    Date of Patent: December 29, 1992
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University Institute for Cancer Research in the City of New York
    Inventors: Paul A. Marks, Richard A. Rifkind, Ronald Breslow, Branko Jursic
  • Patent number: 5055608
    Abstract: The invention provides a class of compounds having two or more nonpolar components connected by a polar group and having polar groups on the termini of the compound.The invention also concerns a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effect to selectively induce terminal differentiation.Moreover, the invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells, thereby inhibiting their proliferation and suppressing oncogenicity.
    Type: Grant
    Filed: June 30, 1989
    Date of Patent: October 8, 1991
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Paul A. Marks, Richard A. Rifkind, Ronald Breslow
  • Patent number: 4920216
    Abstract: This invention concerns a method of substituting a chlorine atom for a predetermined hydrogen atom located within an organic compound which comprises contacting the organic compound containing the predetermined hydrogen atom with an esterifying agent comprising a pyridine ring or a substituted or fused ring derivative of a pyridine ring so as to produce an ester and treating the ester with a chlorinating agent so as to substitute the chlorine atom for the predetermined hydrogen atom. The ester comprises the pyridine ring or the substituted or fused ring derivative of the pyridine ring so positioned within the ester with respect to the predetermined hydrogen atom that a chlorine atom attached to the nitrogen atom of the pyridine ring or substituted or fused ring derivative of the pyridine ring reacts with the predetermined hydrogen atom.
    Type: Grant
    Filed: May 28, 1987
    Date of Patent: April 24, 1990
    Assignee: The Trustees of Columbia in the City of New York
    Inventors: Ronald Breslow, Michael Brandl, Alan D. Adams, Jurgen Hunger
  • Patent number: RE38506
    Abstract: The present invention provides the compound having the structure: wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R1 and R2 are different, R1=R3—N—R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8. The present invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: April 20, 2004
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York
    Inventors: Ronald Breslow, Paul A. Marks, Richard A. Rifkind, Branko Jursic